z-logo
Premium
Time‐Dependent and Immunosuppressive Drug–Associated Adverse Event Profiles in De Novo Kidney Transplant Recipients Converted from Tacrolimus to Sirolimus Regimens
Author(s) -
Felix Maria Julia Pereira,
Felipe Claudia Rosso,
TedescoSilva Hélio,
Osmar MedinaPestana José
Publication year - 2016
Publication title -
pharmacotherapy: the journal of human pharmacology and drug therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.227
H-Index - 109
eISSN - 1875-9114
pISSN - 0277-0008
DOI - 10.1002/phar.1692
Subject(s) - medicine , sirolimus , tacrolimus , calcineurin , adverse effect , mycophenolic acid , tolerability , cumulative incidence , regimen , immunosuppression , gastroenterology , transplantation , prednisone , kidney transplantation , urology
Study Objective To evaluate the safety and tolerability of immunosuppressive drugs used in a planned randomized conversion from a calcineurin inhibitor, tacrolimus, to a mammalian target of rapamycin inhibitor, sirolimus, in de novo kidney transplant recipients. Design Prospective safety analysis of data from a prospective, randomized, open‐label, controlled study. Patients A total of 119 adult kidney transplant recipients who received tacrolimus ( TAC ), mycophenolate sodium ( MPS ), and prednisone between February 2008 and May 2010; after 3 months of this regimen, 60 of these patients were randomized to conversion from TAC to sirolimus ( SRL / MPS group), and 59 patients continued with the TAC regimen ( TAC / MPS group). Measurements and Main Results Both groups were followed for 24 months after transplantation for immunosuppressive regimen–associated and time‐dependent occurrences of adverse events ( AE s) and serious adverse events ( SAE s). Before conversion from TAC to SRL , the cumulative incidence of AE s was 98%; 25% were SAE s. Gastrointestinal AE s (66%) and infections (58%) were the most frequent AE s. The incidences of TAC and MPS dose reductions due to AE s were 1.7% and 12%, respectively. After conversion, no significant differences were noted in the SRL / MPS group versus the TAC / MPS group in the cumulative incidences of AE s (100% vs 98%) and SAE s (27% vs 30%). The most common AE s were gastrointestinal (70% vs 54%, p=0.23) and infection (77% vs 73%, p=0.79) in the SRL / MPS versus TAC / MPS groups. The incidence of aphthous ulcer (28% vs 0%, p=< 0.01), sinusitis (10% vs 0%, p=0.01), dermatitis (15% vs 3%, p=0.03), and dyslipidemia (35% vs 14%, p=0.02) were higher in the SRL / MPS group compared with the TAC / MPS group. Cox proportion regression analysis showed a higher relative risk for gastrointestinal (hazard ratio [ HR] 1.9, 95% confidence interval [ CI ] 1.2–3.01, p<0.05) and skin and subcutaneous tissue ( HR 2.5, 95% CI 1.1–4.1, p<0.05) AE s in the SRL / MPS group compared with the TAC / MPS group. AE ‐related dose reductions occurred in 18.3% of patients receiving SRL and 3.3% of patients receiving TAC . MPS dose reductions due to AE s occurred in 11.7% of patients receiving SRL and 13.6% of patients receiving TAC . Conclusion SRL / MPS treatment was associated with a time‐dependent higher incidence of gastrointestinal and skin and subcutaneous tissue AE s, which occurred mainly during the first 6 months after conversion from TAC / MPS . Although the treatments with SRL or TAC after 3 months of transplantation showed different safety profiles, both regimens demonstrated adequate tolerability, with low rates of early discontinuation related to AE s.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here